PubMed Health⌕ Search

PubMed · 14577792

Diphosphines possessing electronically different donor groups: synthesis and coordination chemistry of the unsymmetrical Di(N-pyrrolyl)phosphino-functionalized dppm analogue Ph2PCH2P(NC4H4)2.

Abstract

The unsymmetrical diphosphinomethane ligand Ph(2)PCH(2)P(NC(4)H(4))(2) L has been prepared from the reaction of Ph(2)PCH(2)Li with PCl(NC(4)H(4))(2). The diphenylphosphino group can be selectively oxidized with sulfur to give Ph(2)P(S)CH(2)P(NC(4)H(4))(2) 1. The reaction of L with [MCl(2)(cod)] (M = Pd, Pt) gives the chelate complexes [MCl(2)(L-kappa(2)P,P')] (2, M = Pd; 3, M = Pt) in which the M-P bond to the di(N-pyrrolyl)phosphino group is shorter than that to the corresponding diphenylphosphino group. However, the shorter Pd-P bond is cleaved on reaction of 2 with an additional 1 equiv of L to give [PdCl(2)(L-kappa(1)P)(2)] 4. Complex 4 reacts with [PdCl(2)(cod)] to regenerate 2, and with [Pd(2)(dba)(3)].CHCl(3) to give the palladium(I) dimer [Pd(2)Cl(2)(mu-L)(2)] 5, which exists in solution and the solid state as a 1:1 mixture of head-to-head (HH) and head-to-tail (HT) isomers. The palladium(II) dimer [Pd(2)Cl(2)(CH(3))(2)(mu-L)(2)] 6, formed by the reaction of [PdCl(CH(3))(cod)] with L, also exists in solution as a mixture of HH and HT isomers, although in this case the HT isomer prevails at low temperature and crystallizes preferentially. Complex 6 reacts with TlPF(6) to give the A-frame complex [Pd(2)(CH(3))(2)(mu-Cl)(mu-L)(2)]PF(6) 7. The reaction of L with [RuCp*(mu(3)-Cl)](4) leads to the dimer [Ru(2)Cp*(2)(mu-Cl)(2)(mu-L)] 8, for which the enthalpy of reaction has been measured. The reaction of L with [Rh(mu-Cl)(cod)](2) gives a mixture of compounds from which the dimer [Rh(2)(mu-Cl)(cod)(2)(mu-L)]PF(6) 9 can be isolated. The crystal structures of 2.CHCl(3), 3.CH(2)Cl(2), 4, 5.(1)/(4)CH(2)Cl(2), 6, 7.2CH(2)Cl(2), 8, and 9.CH(2)Cl(2) are reported.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrew D Burrows, Mary F Mahon, Steven P Nolan, Maurizio Varrone. 2003-11-03. Diphosphines possessing electronically different donor groups: synthesis and coordination chemistry of the unsymmetrical Di(N-pyrrolyl)phosphino-functionalized dppm analogue Ph2PCH2P(NC4H4)2.. https://doi.org/10.1021/ic034487z

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗